Search results

Filters

  • Journals
  • Authors
  • Keywords
  • Date
  • Type

Search results

Number of results: 4
items per page: 25 50 75
Sort by:
Download PDF Download RIS Download Bibtex

Abstract

Background: pharmacists remain on the frontline of public health around the globe and their performance directly impacts patients’ safety. So far, to our knowledge, no European study has been dedicated to their heath-related quality of life (HQoL). Therefore, the primarily aim of our study was to evaluate HQoL of Polish pharmacists utilizing the SF-36 health survey with regard to anthropometric and lifestyle-related variables.
Methods: A total sample screened consisted of 1412 respondents, yet 765 pharmacists (mean age 40, 86.3% females) finally participated in the study. HQoL was assessed with the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36).
Results: The lowest median scores were noted for general health (GH, 50.0) and vitality (V, 60.0) domains. No gender differences regarding physical and mental summary scores were found. Significant difference of HQoL was found among the assessed age groups in several domains, especially physical functioning (PF) and GH (p <0.001) scores, and especially in the group of 51–60-year-old-respondents. Correlations were found between PF (r = –0.29, p <0.001), GH (r = –0.25, p <0.001) and age as well PF (r = –0.27, p <0.001), GH (r = –0.21, p <0.001) and BMI. Self-assessed dietary habits were correlated with PF (r = 0.22, p <0.001), mental health (r = 0.25, p <0.001), GH (r = 0.27, p <0.001) and V (r = 0.30, p <0.001) scores.
Conclusions: The analysis indicates that pharmacists tend to have similar mental and physical burden according to SF-36, with age, BMI and dietary habits as predominant factors influencing their HQoL. The study presents unique values for future comparative analyses related, for instance, to the influence of the ongoing pandemic on HQoL of health-care providers.
Go to article

Authors and Affiliations

Magdalena Kurnik-Łucka
1
Paweł Pasieka
1
Agnieszka Górecka-Mazur
1
Elżbieta Rząsa-Duran
2
Jakub Pękala
1
Krzysztof Gil
1

  1. Department of Pathophysiology, Jagiellonian University Medical College, Kraków, Poland
  2. Pharmacists’ Chamber of Lesser Poland, Kraków, Poland
Download PDF Download RIS Download Bibtex

Abstract

Eating disorders are a heterogeneous group of diseases affecting mainly young people in devel-oped countries. Among them, anorexia nervosa (AN) is the one with the highest mortality, up to five times higher compared to healthy individuals. The etiology of this medical condition is complex and still un-certain. However, disturbances of the autonomic nervous system (ANS) and increased lipolysis resulting in a decrease of the adipose tissue volume are common findings among AN patients. Since ANS is directly connected to adipocyte tissue, thus significantly affecting the body’s metabolic homeostasis, we suspect that this relationship may be a potential pathophysiological underpinning for the development of AN. In this narrative review, we have analyzed scientific reports on ANS activity in AN considering different phases of the disease in humans as well as animal models. Due to the different effects of the disease itself on the ANS as well as specific variations within animal models, the common feature seems to be dysre-gulation of its function without the identification of one universal pattern. Nonetheless, higher norepi-nephrine concentrations have been reported in adipocyte tissue, suggesting local dominance of the sym-pathetic nervous system. Further studies should explore in depth the modulation of sympathetic in adipose tissue factor and help answer key questions that arise during this brief narrative review.
Go to article

Authors and Affiliations

Andrzej Boryczko
1 2
Kamil Skowron
1
Magdalena Kurnik-Łucka
1
Krzysztof Gil
1

  1. Department of Pathophysiology, Jagiellonian University Medical College, Kraków, Poland
  2. Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Kraków, Poland
Download PDF Download RIS Download Bibtex

Abstract

The need for mass population vaccination against Covid-19 poses a public health problem. Allergic symptoms occurring after the 1st dose of the vaccine may result in resignation from the admin-istration of the 2nd dose. However, the majority of patients with mild and/or non-immediate symptoms may be safely vaccinated. The only absolute contraindication to administration of the vaccine is an anaphylactic reaction to any of its ingredients. Polyethylene glycol (PEG), widely used as an excipient in various vaccines, is considered the primary cause of allergic reactions associated with administration of Comirnaty (Pfizer/BioNTech) and Covid-19 Vaccine (Moderna) vaccines. However, hypersensitivity to PEG reported to date seems very rare, considering its widespread use in multiple everyday products, including medicines and cosmetics. In the paper, current literature data describing mechanisms of hy-persensitivity reactions to PEG, their clinical symptoms and diagnostic capabilities are presented. Un-doubtedly, the issue of hypersensitivity to PEG warrants further research, while patients with the diagnosis require individual diagnostic and therapeutic approach.
Go to article

Bibliography

1. Robinson L.B., Landman A.B., Shenoy E.S., et al.: Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination. J Allergy Clin Immunol Pract. 2021 Aug; 9 (8): 3200–3202.
2. Krantz M.S., Bruusgaard-Mouritsen M.A., Koo G., Phillips E.J., Stone C.A., Garvey L.H.: Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don’t give up on the second dose! Allergy. 2021 Sep; 76 (9): 2916–2920. doi: 10.1111/all.14958
3. CDC COVID-19 Response Team, FDA: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. Centers for Disease Control and Prevention. 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm (Accessed 02 Apr 2021).
4. CDC COVID-19 Response Team, Administration FDA: Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 125e9.
5. Narodowy Instytut Zdrowia: Niepożądane Odczyny Poszczepienne po szczepionkach przeciw COVID-19 w Polsce. Raport za okres 27.12.2020–31.07.2021. https://www.pzh.gov.pl/wp-content/uploads/2021/08/Raport-NOP-do-31.07.2021.pdf (Accessed 10 Aug 2021).
6. Cabanillas B., Novak N.: Allergy to COVID-19 vaccines: A current update. Allergol Int. 2021 Jul; 70 (3): 313–318. doi: 10.1016/j.alit.2021.04.003
7. Kruszewski J., Cichocka-Jarosz E., Czarnobilska E., et al.: Recommendations of the Polish Society of Allergology on the qualification of person with allergies and anaphylaxis to vaccination against COVID-19. Alergologia Polska — Polish Journal of Allergology. 2021; 8, 1: 1–8. doi: https://doi.org/10.5114/pja.2021.10422
8. Hyun-Jun J., Chan Young S., Kyu-Bong K.: Safety Evaluation of Polyethylene Glycol (PEG) Compounds for Cosmetic Use. Toxicol Res. 2015 Jun; 31(2):105–136. doi: 10.5487/TR.2015.31.2.105
9. Wenande E., Garvey L.H.: Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy 2016 Jul; 46 (7): 907–922. doi: 10.1111/cea.12760
10. Stone C.A. Jr., Liu Y., Relling M.V., et al.: Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2019 May– Jun; 7 (5): 1533–1540.e8. doi: 10.1016/j.jaip.2018.12.003
11. Castells M.C., Phillips E.J.: Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2021 Feb; 384 (7): 643–649. doi: 10.1056/NEJMra2035343
12. Klimek L., Jutel M., Akdis C.A., et al.: ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines — An EAACI-ARIA Position Paper. Allergy. 2021 Jun; 76 (6): 1624–1628. doi: 10.1111/all.14726
13. Klimek L., Bergmann K.C., Brehler R., et al.: Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI. Allergo J Int. 2021 Apr; 1–17. doi: 10.1007/s40629-021-00165-7
14. Rutkowski K., Mirakian R., Till S., Rutkowski R., Wagner A.: Adverse reactions to COVID-19 vaccines: A practical approach. Clin Exp Allergy. 2021 Jun; 51 (6): 770–777. doi: 10.1111/cea.13880
15. Pawliczak R.: Alergologia-kompendium. In: Pawliczak R., ed. Mechanizmy uczulenia. 1st Ed. Poznań: Termedia Wydawnictwa Medyczne; 2013; 31–35.
16. Giavina-Bianchi P., Kalil J.: Polyethylene Glycol Is a Cause of IgE-Mediated Anaphylaxis. J Allergy Clin Immunol Pract. 2019; 7 (6): 1874–1875. doi: 10.1016/j.jaip.2019.05.001
17. Wenande E.C., Skov P.S., Mosbech H., Poulsen L.K., Garvey L.H.: Inhibition of polyethylene glycol- induced histamine release by monomeric ethylene and diethylene glycol: a case of probable polyethylene glycol allergy. J Allergy Clin Immunol. 2013 May; 131 (5): 1425–1427. doi: 10.1016/j.jaci.2012.09.037
18. Borderé A., Stockman A., Boone B., et al.: A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid. Contact Dermatitis. 2012 Dec; 67 (6): 376–378. doi: 10.1111/j.1600-0536.2012.02104.x
19. Wylon K., Dölle S., Worm M.: Polyethylene glycol as a cause of anaphylaxis. Allergy Asthma Clin Immunol. 2016 Dec; 12: 67. doi: 10.1186/s13223-016-0172-7. eCollection 2016.
20. Cox F., Khalib K., Conlon N.: PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol. J Clin Pharmacol. 2021 Jun; 61 (6): 832–835. doi: 10.1002/jcph.1824. Epub 2021 Feb 28.
21. Greenhawt M., Abrams E.M., Oppenheimer J.: The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World. J Allergy Clin Immunol Pract. 2021 Apr; 9 (4): 1438–1441. doi: 10.1016/j.jaip.2021.01.022
22. Bruusgaard-Mouritsen M.A., Jensen B.M., Poulsen L.K., Duus Johansen J., Garvey L.H.: Optimizing investigation of suspected allergy to polyethylene glycols. J Allergy Clin Immunol. 2021 May; S0091-6749(21)00825-3. doi: 10.1016/j.jaci.2021.05.020
23. Pickert J., Hennighausen I., Mühlenbein S., Möbs C., Pfützner W.: Immediate-Type Hypersensitivity to Polyethylene Glycol (PEG) Including a PEG-containing COVID-19 Vaccine Revealed by Intradermal Testing. J Investig Allergol Clin Immunol. 2021 Jun; 15: 0. doi: 10.18176/jiaci.0720
24. Wolfson A.R., Robinson L.B., Li L., et al.: First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. J Allergy Clin Immunol Pract. 2021 Sep; 9 (9): 3308–3320.e3. doi: 10.1016/j.jaip.2021.06.010
25. Santos A.F., Alpan O., Hoffmann H.J.: Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice. Allergy. 2021 Aug; 76 (8): 2420–2432. doi: 10.1111/all.14747
26. Ansotegui I.J., Melioli G., Canonica G.W., et al.: IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J. 2020 Feb; 13 (2): 100080. doi: 10.1016/j.waojou.2019.100080
27. Spiewak R.: Eczema and food allergy — is there a causal relationship? Przegl Lek. 2013; 70 (12): 1051– 1055.
28. Braun W.: Contact allergies to polyethylene glycols. Z Haut Geschlechtskr. 1969 Jun; 44 (11): 385– 389.
29. Bajaj A.K., Gupta S.C, Chatterjee A.K., Singh K.G.: Contact sensitivity to polyethylene glycols. Contact Dermatitis. 1990 May; 22 (5): 291–292. doi: 10.1111j.16000536.1990.tb01602.x
30. Özkaya E, Kılıç S.: Polyethylene glycol as marker for nitrofurazone allergy: 20 years of experience from Turkey. Contact Dermatitis. 2018 Mar; 78 (3): 211–215. doi: 10.1111/cod.12931
31. Caballero M.L., Quirce S.: Delayed Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review. J Investig Allergol Clin Immunol. 2020; 30 (6): 400–408. doi: 10.18176/jiaci.0562
32. Bruusgaard-Mouritsen M.A., Johansen J.D., Garvey L.H.: Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. Clin Exp Allergy. 2021 Mar; 51 (3): 463– 470. doi: 10.1111/cea.13822
Go to article

Authors and Affiliations

Maria Czarnobilska
1
Małgorzata Bulanda
2
Magdalena Kurnik-Łucka
1
Krzysztof Gil
1

  1. Department of Pathophysiology, Jagiellonian University Medical College, Kraków, Poland
  2. Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Kraków, Poland
Download PDF Download RIS Download Bibtex

Abstract

Up to 2% of pregnancies may be extrauterine. Despite reproductive problems, they might increase the risk of serious complications. We present a case report of a 31-year-old woman with two extrauterine pregnancies — tubal and ovarian, which occurred at the same side with little time difference. In addition, we aimed to examine possible reasons underlying this rare pathology. Thus, surgically removed tissue specimens were morphologically assessed and further compared with specimens from healthy control patients. Telocytes were analysed in detail due to their pivotal role in the female repro-ductive system. Our study had observational character and obvious limitations typical for a clinical case. Yet, such a clinical case of two ectopic pregnancies has not been previously reported in the literature.
Go to article

Authors and Affiliations

Anna Wrona
1
Veronika Aleksandrovych
2
Anna Gil
3
Magdalena Kurnik-Łucka
2
Jerzy A. Walocha
3
Krzysztof Gil
2

  1. Gynecology and Obstetrics Ward with Gynecologic Oncology Subdivision, J. Śniadecki’s Specialistic Hospital, Nowy Sącz, Poland
  2. Department of Pathophysiology, Jagiellonian University Medical College, Kraków, Poland
  3. Department of Anatomy, Jagiellonian University Medical College, Kraków, Poland

This page uses 'cookies'. Learn more